


CLAIMS

We claim:

- 5 1. A compound of Formula I



wherein

- 10 Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy, or Ar is 2,3-dihydrobenzofuran-4-yl;

R¹ is C₁₋₆alkyl or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy;

15

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R², R³, R⁴, and R⁵ are independently hydrogen, halo, C₁₋₃alkoxy, or C₁₋₆alkyl;

20

or R² and R³ taken together, R³ and R⁴ taken together, or R⁴ and R⁵ taken together are -O(CH₂)₂₋₃- or -O(CH₂)₁₋₂O-;

R⁶ is selected from the group consisting of hydrogen, C₁₋₉alkyl, C₃₋₇cycloalkyl,

- 25 C₁₋₆alkoxy, C₁₋₂perfluoroalkyl, -CH₂OC₁₋₃alkyl, -(CH₂)₁₋₂CO₂R⁷, -(CH₂)₁₋₂CO₂NR⁷₂, -NR⁷₂, -CH₂Cl, -CH₂OCOMe, -CH₂OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl where phenyl is

optionally substituted with 1-3 substituents selected from halogen, C₁₋₃alkoxy, C₁₋₂perfluoroalkyl, C₁₋₂perfluoroalkoxy, and nitro; and

R⁷ is hydrogen or C₁₋₆alkyl;

5

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

2. The compound of claim 1 where Ar and R¹ are each phenyl optionally substituted with 1-3 substituents selected from halogen, C₁₋₆alkyl, and C₁₋₆alkoxy.

10

3. The compound of claim 2 where Ar is phenyl or 4-chlorophenyl and R¹ is phenyl.

4. The compound of claim 3 where R⁴ is C₁₋₃ alkoxy.

15

5. The compound of claim 4 selected from the group consisting of

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbaldehyde;

20 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

25 1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-heptanone;

1-[1-(2-(4-chlorophenyl)-2-phenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

30

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-propan-1-one;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-butan-1-one;

5 cyclopropyl-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-methanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-phenyl-methanone;

10 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid amide;

15 1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methylamide;

20 1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methyl ester; and

1-[1-(2,2-diphenyl-ethyl)-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;


or a pharmaceutically acceptable salt or solvate thereof.

25

6. The compound of claim 3 where R^3 and R^4 taken together are $-O(CH_2)_{2-3}-$ or $-O(CH_2)_{1-2}O-$.

7. A method of treatment for circadian-related disorders comprising
30 administration of a therapeutic amount of a compound of Formula Ia

37



where:

- 5 Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy, or Ar is 2,3-dihydrobenzofuran-4-yl;

R¹ is hydrogen, C₁₋₆alkyl, or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy;

10

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R², R³, R⁴, and R⁵ are independently hydrogen, halo, C₁₋₃alkoxy, or C₁₋₆alkyl;

15

or R² and R³ taken together, R³ and R⁴ taken together, or R⁴ and R⁵ taken together are -O(CH₂)₂₋₃- or -O(CH₂)₁₋₂O-;

R⁶ is selected from hydrogen, C₁₋₉alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy,

- 20 C₁₋₂perfluoroalkyl, -CH₂OC₁₋₃alkyl, -(CH₂)₁₋₂CO₂R⁷, -(CH₂)₁₋₂CO₂NR⁷₂, -NR⁷₂, -CH₂Cl, -CH₂OCOMe, -CH₂OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₃alkoxy, C₁₋₂perfluoroalkyl, C₁₋₂perfluoroalkoxy, and nitro; and

25

R⁷ is hydrogen or C₁₋₆alkyl;

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

8. A method of treating sleep disorders comprising administration of a therapeutic amount of the compound of claim 7.
9. A composition useful for treating a patient having circadian-related disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.
10. A composition useful for treating a patient having sleep disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.